Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of an agreement with Bristol Myers Squibb, in which Tempus delivers de-identified transcriptomic datasets to enhance Bristol Myers Squibb’s research efforts on new biomarkers related to certain cancer subtypes. The agreement also enables rapid access to new datasets with standard terms and custom data models to inform emerging research decisions. As precision medicine continues to evolve, RNA has become the new frontier in the search for critical molecular insights in oncology. Bristol Myers Squibb is leveraging Tempus’ vast library of such multi-modal data to advance its efforts in discovering and developing innovative therapies for cancer patients worldwide.
As part of the expanded agreement, Bristol Myers Squibb, a leading global biopharmaceutical company, has licensed additional data cohorts across multiple tumor types, with access to terabytes of new data. Each company is focused on identifying better ways to treat patients with unmet needs through the analysis of multi-modal data including whole-transcriptome sequencing data.
“With Tempus’ whole-transcriptome sequencing datasets, it’s now possible to analyze known and novel RNA expression targets connected to real-world treatments and outcomes,” said Ryan Fukushima, Chief Operating Officer of Tempus. “Our work with Bristol Myers Squibb has made it possible to transform terabytes of data into clinically relevant insight by stratifying diseases into key molecular subtypes and uncovering potentially better ways to treat patients going forward.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
To read more Press Release articles, click here.